Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

NCT01256489 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis Syndrome (TENS) are rare (\~3 in 1 million). No eligible subjects have been identified.

Conditions

Interventions

Sponsor

Massachusetts Eye and Ear Infirmary